Sanofi and GSK Report Results of its COVID-19 Vaccine in a P-II Study Across All Adult Age Groups
Shots:
- The vaccine has achieved strong rates of neutralizing antibody responses- in line with those measured in people who have recovered from COVID-19- in all adult age groups in a P-II study
- The results showed 95%-100% seroconversion following the second injection in all age groups (18-95yrs. old) & across all doses- with acceptable tolerability & no safety concerns. The high immune response following the single dose in patients with prior infection shows strong booster potential of the vaccine
- The companies are planning to start the P-III study in the coming weeks and are expecting the vaccine to be approved in Q4’21- following the positive P-III outcomes & regulatory reviews
Ref: Sanofi | Image: Sanofi
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com